Opinion|Videos|November 13, 2026

What Makes SERENA-6 Compelling: Quality of Life, ctDNA Clearance, and the PADA-1 Heritage

The data were certainly compelling.

Premji: The data were certainly compelling. We can always raise questions about trial design, but my understanding is that SERENA-6 was designed from the very exciting PADA-1 data, which showed that a ctDNA-guided switch on emergent ESR1 was a viable approach. The compelling parts for me go beyond the novel concept of swapping in a new endocrine agent to address the believed root cause of resistance.

Premji: The quality-of-life data were exciting — improvement in median time to deterioration out to 21 months in the camizestrant arm, with meaningful gains in domains our patients feel every day: bone pain, shortness of breath, fatigue — symptoms that affect their function and their actual quality of life. The ctDNA clearance results were also compelling — a little over half of patients completely cleared their circulating tumor DNA, and more than 99% showed a drop in the variant allele fraction of ESR1-mutant alleles.

Premji: There are caveats. The trial looked at the subpopulation of patients who also had PIK3CA mutations, and there are nuances when multiple ESR1 mutations are present. But in general, it is a very exciting approach. I know it has an FDA approval, and it is something I’m going to bring up with all of my patients — showing them the data and what we know. We have an accelerated approval pending full approval on the confirmatory readout. Still, there are questions in my mind.


Related to this article